I. Gardner
Impact in
- Pharmacology top 5%
- Pharmacogenetics and Drug Metabolism
- Antibiotics Pharmacokinetics and Efficacy
-
- Environmental Toxicology and Ecotoxicology
- Effects and risks of endocrine disrupting chemicals
Papers in
-
- Receptor Mechanisms and Signaling 2
- Biochemical and Molecular Research 2
-
- Computational Drug Discovery Methods 4
- Co-authors
- Masoud Jamei (5 shared papers)Lisa M. Almond (2 shared papers)Angeleen Fleming (2 shared papers)Stéphane Berghmans (2 shared papers)Paul Butler (2 shared papers)W. Alderton (2 shared papers)Zoe Golder (2 shared papers)Frances M. Richards (1 shared paper)
- Journals
- Xenobiotica (5 papers)CPT Pharmacometrics & Systems Pharmacology (2 papers)Toxicology Letters (2 papers)Current Opinion in Toxicology (1 paper)Clinical Pharmacology & Therapeutics (1 paper)
- Partner nations
- United KingdomUnited StatesGermany
In The Last Decade
I. Gardner
12 papers receiving 432 citations
Peers
Comparison fields: 5 of 84
- Pharmacology 134
- Health, Toxicology and Mutagenesis 55
- Cell Biology 58
- Pharmacology 46
- Pharmaceutical Science 15
Countries citing papers authored by I. Gardner
This map shows the geographic impact of I. Gardner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I. Gardner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I. Gardner more than expected).
Fields of papers citing papers by I. Gardner
This network shows the impact of papers produced by I. Gardner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I. Gardner. The network helps show where I. Gardner may publish in the future.
Co-authors
The 25 scholars most cited alongside I. Gardner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2010 | 102 | |
| 2 | 2013 | 88 | |
| 3 | 2015 | 70 | |
| 4 | 2008 | 49 | |
| 5 | 2018 | 46 | |
| 6 | 2014 | 28 | |
| 7 | Bioactivation and covalent binding of hydroxyfluperlapine in human neutrophils: implications for fluperlapine-induced agranulocytosis. | 2000 | 21 |
| 8 | 1995 | 16 | |
| 9 | 2009 | 11 | |
| 10 | 2019 | 7 | |
| 11 | 2008 | 5 | |
| 12 | 2008 | 2 | |
| 13 | 2025 | 0 | |
| 14 | 2018 | 0 | |
| 15 | 2016 | 0 |
About I. Gardner
I. Gardner is a scholar working on Molecular Biology, Computational Theory and Mathematics, Small Animals, Oncology and Pharmacology, having authored 15 papers that have together received 445 indexed citations. Recurring topics across this work include Computational Drug Discovery Methods (4 papers), Pharmacogenetics and Drug Metabolism (3 papers), Animal testing and alternatives (3 papers), Drug Transport and Resistance Mechanisms (2 papers), Receptor Mechanisms and Signaling (2 papers), Zebrafish Biomedical Research Applications (2 papers), Effects and risks of endocrine disrupting chemicals (2 papers) and Biochemical and Molecular Research (2 papers). The work is most often cited by research in Pharmacology (134 citations), Health, Toxicology and Mutagenesis (55 citations), Cell Biology (58 citations), Pharmacology (46 citations) and Pharmaceutical Science (15 citations). I. Gardner has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Masoud Jamei, Lisa M. Almond, Angeleen Fleming, Stéphane Berghmans, Paul Butler, W. Alderton, Zoe Golder, Frances M. Richards, Amita Joshi and Ciarán Fisher. Their work appears in journals such as Xenobiotica, CPT Pharmacometrics & Systems Pharmacology, Toxicology Letters, Current Opinion in Toxicology and Clinical Pharmacology & Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.